VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC

Takayuki Yoshino, MD, PhD , National Cancer Center Hospital, Chiba, Japan, shares results of the Phase III PARADIGM trial (NCT02394795) investigating anti-EGFR panitumumab antibody plus mFOLFOX6 versus the anti-VEGFR bevacizumab antibody plus mFOLFOX6 as first-line treatment in patients with left-sided RAS wild-type metastatic colorectal cancer (mCRC). The primary endpoint of the PARADIM trial was overall-survival (OS) and secondary endpoints included progression-free survival (PFS), response rate (RR) and duration of response (DOR). This Phase III study demonstrated a superior OS rate with panitumumab plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter